Cabotegravir-Hormone PK/PD Interactions for HIV Prevention (NCT07672717)
CHIPP-PrEP: Cabotegravir-Hormone Interrogation of Pharmacokinetics/Pharmacodynamics (PK/PD) for HIV Prevention
🩺 Plain-English Summary (8th-Grade Level)
This is a research study to better understand how long-acting cabotegravir (CAB-LA) works to prevent HIV in people. This study will also evaluate the impact of endogenous and therapeutic hormones on CAB-LA pharmacology. The investigators will also evaluate if participants experience any medical problems when taking CAB-LA.
Who can join: Review the eligibility criteria below.
Location: Johns Hopkins School of Medicine, Drug Development Unit — Baltimore, Maryland
Age range: 19 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- Johns Hopkins School of Medicine, Drug Development Unit — Baltimore, Maryland
📞 Contact the Study Coordinator
Phone: (410) 955-1201
Email: pakoija1@jh.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in HIV
- CD4 CAR+ ZFN-modified T Cells in HIV Therapy — Philadelphia, Pennsylvania
- Cisgender Female Patients Who Start on Long Acting Cabotegravir for PrEP — Orlando, Florida
- Safety Study of Zinc Finger Nuclease CCR5-modified Hematopoietic Stem/Progenitor Cells in HIV-1 Infected Patients — Duarte, California
- Urban Gardening and Peer Nutritional Counseling for People With HIV and Food Insecurity — Azua,
- Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of 16055 NFL Delta Gly4 Env Protein Trimer and Trimer 4571 Combined With 3M-052-AF + Alum Adjuvant and Ad4-Env145NFL Viral Particles as Heterologous Prime-boost Regimens in Adult Participants Without HIV. — Birmingham, Alabama
- Wellness, Intervention Strategies and HIV Care — Oakland, California
Explore by condition: All HIV clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.